The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research
HONG KONG, Feb. 28, 2024 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody（cadonilimab）combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer had be...
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...
Lenovo Visuals Business Unit Cements Status as Industry Leader
HONG KONG, Oct. 18, 2019 /PRNewswire/ -- Lenovo's (HKSE: 992) (ADR: LNVGY) exceptional monitors and messaging campaigns have cemented its status as a leader in the electronics industry. Lenovo Visuals Business Unit, a team dedicated to delivering industry-leading display solutions, recently unvei...
Lenovo and Microsoft Deepen Strategic Ties across Devices
REDMOND, Wash. and BEIJING, Aug. 23, 2016 /PRNewswire/ -- Microsoft Corp. and Lenovo announced on Friday a deepening of their strategic relationship. Lenovo will load Microsoft's productivity apps - including Microsoft Office, OneDrive and Skype - on select Lenovo devices that use the Android™ op...
